보고서 요약(국문)

개요
전 세계 신경섬유종증 2형 시장은 2022년 XX백만 달러에 도달했으며, 2023년부터 2030년까지 연평균 성장률(CAGR) XX%로 성장하여 2030년에는 XX백만 달러에 이를 것으로 예상됩니다.
신경섬유종증 2형(NF2)은 중추신경계(CNS)에 다발성 종양이 발생하는 상염색체 우성 유전 질환입니다. 전정신경초종은 신경섬유종증 2형과 가장 흔하게 관련된 종양입니다. 신경섬유종증 2형의 증상은 어느 연령에서든 나타날 수 있지만, 일반적으로 청소년기 또는 20대 초반에 나타납니다.
NF2 유전자는 멀린 단백질 생성을 담당합니다. 신경계, 특히 뇌와 척수에서 신경 세포(뉴런)를 둘러싸고 절연하는 슈반 세포에서 이 단백질이 생성됩니다. 종양 억제인자인 멀린은 세포가 통제되지 않거나 너무 빠르게 증식하고 분열하는 것을 방지합니다. 시장 동향: 성장 동인 및 제약 요인
연구 개발 활동 증가
연구 개발에 대한 관심 증가와 치료 옵션에 대한 수요 증가는 시장 성장을 견인할 것으로 예상됩니다. 임상 연구 증가는 규제 당국의 적극적인 지원을 받고 있으며, 이는 신경섬유종증 2형 시장 성장을 촉진할 것으로 전망됩니다.
유전자 검사의 증가 또한 치료 수요를 증가시킬 것으로 예상됩니다. 부작용이 최소화되고 환자 풀이 확대됨에 따라 치료 접근성이 향상되기 때문입니다. MEK 억제제 및 TKI와 같은 표적 치료제의 개발과 고무적인 임상 시험 결과는 환자들에게 더 많은 치료 옵션을 제공합니다. 따라서 위의 요인들은 예측 기간 동안 시장 성장을 촉진할 것으로 예상됩니다.
제약 요인
의약품 승인 부족 및 제한된 치료 옵션
의약품 승인 부족과 시장의 제한적인 치료 옵션은 시장 성장을 저해할 것으로 예상됩니다. 확립된 효과적인 치료법의 부재는 환자들에게 불확실성을 야기하고, 의료 서비스 제공자들은 진단 절차 및 치료 개입을 줄일 가능성이 있습니다. 높은 의약품 제조 비용 또한 시장 성장에 영향을 미칠 수 있습니다.
세분화 분석
전 세계 신경섬유종증 2형(NF2) 시장은 종양 유형, 치료 유형, 최종 사용자 및 지역별로 세분화됩니다.
수술 부문이 시장 점유율의 49.8%를 차지했습니다.
수술은 대부분의 경우 1차 치료법으로 간주됩니다. NF2로 인해 발생하는 대부분의 뇌종양은 종양 제거 수술을 통해 치료됩니다. 개두술은 신경외과 의사가 종양에 접근하기 위해 두개골의 일부를 일시적으로 제거하는 수술 기법입니다. 인공와우라고 하는 전기 장치를 수술적으로 이식하는 것도 1차 치료법 중 하나입니다.
인공와우는 NF2에 사용되는 두 가지 유형의 인공와우 중 하나입니다. 대부분의 경우 수술이 여전히 주요 치료법입니다. 수술은 일반적으로 청력을 완전히 상실한 환자 또는 청력을 담당하는 신경을 보존할 수 있는 작은 종양이 있는 환자에게 시행됩니다. 따라서 위의 요인들은 수술 부문이 시장을 주도하는 위치를 유지하는 데 기여할 것으로 예상됩니다.
지리적 분석
북미는 전 세계 신경섬유종증 2형 시장에서 상당한 비중을 차지할 것으로 예상됩니다.
북미는 잘 갖춰진 의료 인프라, 고품질 진단 절차 및 장비, 그리고 이 지역의 의약품 생산 증가로 인해 예측 기간 동안 시장 점유율에서 주도적인 위치를 차지할 것으로 예상됩니다.
진단 절차에 대한 개인의 인식 증가 또한 시장 성장을 견인할 것으로 예상됩니다. 인식이 높아지면 질병의 조기 발견과 치료 진행이 용이해져 수술 및 약물 수요가 증가할 것입니다. 따라서 위의 요인들은 이 지역의 시장 성장을 촉진할 것으로 예상됩니다.
COVID-19 영향 분석
COVID-19는 시장 성장에 전례 없는 영향을 미쳤습니다. 봉쇄 조치로 인해 의료 서비스 접근성이 크게 저하되었고, 국가 간 공급망이 차질을 빚었습니다. 해당 약물에 대한 임상 시험은 회사가 코로나19 치료제 생산에 관심을 돌리면서 중단되었습니다.
시장 세분화
종양 유형별
• 전정신경초종
• 수막종
• 기타 종양
치료 유형별
• 수술
o 종양 제거
o 정위 방사선 수술
o 기타
• 방사선 치료
• 약물 치료
o 라파티닙
o 셀루메티닙
o 베바시주맙
o 기타
• 기타
최종 사용자별
• 병원
• 암 센터
• 기타
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 이탈리아
o 스페인
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
경쟁 환경
상당한 시장 점유율을 차지하는 주요 기업으로는 Manus Aktteva Biopharma LLP, AstraZeneca Plc 등이 있습니다. OCEAN PHARMACEUTICAL, Vivace Therapeutics, Ikena Oncology, Inc., Recursion Pharmaceuticals Inc. 등
보고서 구매 이유:

• 종양 유형, 치료 유형, 최종 사용자 및 지역별 글로벌 신경섬유종증 2형 시장 세분화를 시각화하고 주요 상업 자산 및 기업을 파악합니다.

• 트렌드 및 공동 개발 분석을 통해 사업 기회를 식별합니다.

• 모든 세그먼트를 포함한 신경섬유종증 2형 시장 수준의 다양한 데이터가 담긴 Excel 데이터 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석을 담은 PDF 보고서를 제공합니다.

• 주요 기업의 핵심 제품을 모두 포함하는 제품 맵핑을 Excel 파일로 제공합니다.

글로벌 신경섬유종증 2형 시장 보고서는 약 57개의 표, 65개의 그림, 179페이지로 구성됩니다.
대상 고객 (2023년)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 연구 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Neurofibromatosis Type 2 Market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing at a CAGR of XX% during the forecast period 2023-2030.
Neurofibromatosis type 2 (NF2) is an autosomal dominant disorder characterized by the development of multiple tumors involving the central nervous system (CNS). Vestibular schwannomas are the tumors most frequently linked to neurofibromatosis type 2. The onset of neurofibromatosis type 2 symptoms can occur at any age, but they typically manifest in adolescence or the early twenties.
The NF2 gene codes for the production of the merlin protein. The neurological system, in especially the Schwann cells that encircle and insulate the nerve cells, or neurons, in the brain and spinal cord, produces this protein. As a tumor suppressor, merlin prevents cells from proliferating and dividing uncontrollably or too quickly.
Market Dynamics: Drivers & Restraints
Rise in research and developmental activities
Increasing focus on research and development and increasing demand for treatment options are expected to drive market growth. The increase in clinical studies is well supported by regulatory authorities which is expected to drive the growth of the neurofibromatosis Type 2 market growth.
The increasing genetic testing is also expected to increase the demand for the treatment of the disease as the side effects are minimal and the patient pool plays a major role in increasing the access to the available treatments. The development of targeted drugs like MEK inhibitors and TKIs, with encouraging clinical trial results increases the options for the patients suffering frm the disease. Thus, the above factors are expected to increase the market growth in the forecast period.
Restraint
Lack of drug approvals and fewer treatment options
Lack of drug approvals as well as limited treatment options in the market are expected to hinder the market growth. The absence of established, effective treatments creates uncertainty for patients, and healthcare providers are expected to reduce diagnostic procedures and also intervention in treatment procedures. The high cost of manufacturing drugs can also affect the market growth.
Segment Analysis
The global neurofibromatosis type 2 market is segmented based on tumor type, treatment type, end-user and region.
Surgery segment accounted for 49.8% of the market share
Surgery is considered to be the first line of treatment in most of the cases. Brain tumor surgery to remove the tumor is the usual course of treatment for the majority of brain tumors that arise with NF2. A craniotomy is a surgical technique where a neurosurgeon temporarily removes a part of the skull to access the tumor. An electrical device known as a hearing implant is surgically implanted as the first line of treatment.
Cochlear implants are one of the two types of hearing implants used in NF2. In most cases, surgery is still the primary course of treatment. Surgery is typically performed on patients who have lost all hearing or on those who have a tiny tumor where it is feasible to meaningfully try to preserve the nerve that provides hearing. Thus, the above factors are expected to hold the surgery segment in the dominant position.
Geographical Analysis
North America is expected to hold a significant position in the global neurofibromatosis type 2 market share
North America is expected to hold a dominant position in the market share during the forecast period due to the well-equipped health infrastructure, high-quality diagnostic procedures and equipment, and the increase in pharmaceutical production in the region.
The increase in the awareness among individuals of diagnostic procedures is also expected to drive market growth. An increase in awareness will increase early detection of the disease condition and proceed with the treatment options which increases the demand for the surgical as well as the drugs that are being allotted for the disease. Thus, the above factors are expected to drive the market growth in the region.
COVID-19 Impact Analysis
COVID-19 has affected the market growth unprecedently. There are many disruptions in healthcare access due to the lockdown and the supply chain has been disrupted among the borders of the country. The clinical trials of the drugs have been halted due to the shift of the company's interest in the production of COVID-19 drugs.
Market Segmentation
By Tumor Type
• Vestibular Schwannomas
• Meningiomas
• Other Tumors
By Treatment Type
• Surgery
o Tumor Removal
o Stereotactic Radiosurgery
o Others
• Radiation Therapy
• Drug Therapy
o Lapatinib
o Selumetinib
o Bevacizumab
o Others
• Others
By End-User
• Hospitals
• Cancer Centers
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The leading companies with a significant market share include Manus Aktteva Biopharma LLP, AstraZeneca Plc, OCEAN PHARMACEUTICAL, Vivace Therapeutics, Ikena Oncology, Inc., Recursion Pharmaceuticals Inc. among others
Why Purchase the Report?
• To visualize the global neurofibromatosis type 2 market segmentation based on tumor type, treatment type, end-user, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of neurofibromatosis type 2 market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global neurofibromatosis type 2 market report would provide approximately 57 tables, 65 figures, and 179 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Tumor Type
3.2. Snippet by Treatment Type
3.3. Snippet by End-User
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rise in research and developmental activities
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. Lack of drug approvals and fewer treatment options
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Epidemiology Statistics
5.4. Pricing Analysis
5.5. Regulatory Analysis
5.6. Russia-Ukraine War Impact Analysis
5.7. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. Tumor Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Tumor Type
7.1.2. Market Attractiveness Index, By Tumor Type
7.2. Vestibular Schwannomas
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Meningiomas
7.4. Other Tumors
8. By Treatment Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.1.2. Market Attractiveness Index, By Treatment Type
8.2. Surgery
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.2.3. Tumor Removal
8.2.4. Stereotactic Radiosurgery
8.2.5. Others
8.3. Radiation Therapy
8.4. Drug Therapy
8.4.1. Lapatinib
8.4.2. Selumetinib
8.4.3. Bevacizumab
8.4.4. Others
8.5. Others
9. By End-User
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.1.2. Market Attractiveness Index, By End-User
9.2. Hospitals
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Cancer Centers
9.4. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Tumor Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Tumor Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Tumor Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Tumor Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Tumor Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Manus Aktteva Biopharma LLP*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. AstraZeneca Plc
12.3. OCEAN PHARMACEUTICAL
12.4. Vivace Therapeutics
12.5. Ikena Oncology, Inc.
12.6. Recursion Pharmaceuticals Inc.
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Manus Aktteva Biopharma LLP, 4.	Key Developments, AstraZeneca Plc, OCEAN PHARMACEUTICAL, Vivace Therapeutics, Ikena Oncology, Inc., Recursion Pharmaceuticals Inc.

표 목록 (Tables)

List of Tables

Table 1 Global Neurofibromatosis Type 2 Market Value, By Tumor Type, 2023, 2027 & 2031 (US$ Million)

Table 2 Global Neurofibromatosis Type 2 Market Value, By Treatment Type, 2023, 2027 & 2031 (US$ Million)

Table 3 Global Neurofibromatosis Type 2 Market Value, By End-User, 2023, 2027 & 2031 (US$ Million)

Table 4 Global Neurofibromatosis Type 2 Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 5 Global Neurofibromatosis Type 2 Market Value, By Tumor Type, 2023, 2027 & 2031 (US$ Million)

Table 6 Global Neurofibromatosis Type 2 Market Value, By Tumor Type, 2022-2031 (US$ Million)

Table 7 Global Neurofibromatosis Type 2 Market Value, By Treatment Type, 2023, 2027 & 2031 (US$ Million)

Table 8 Global Neurofibromatosis Type 2 Market Value, By Treatment Type, 2022-2031 (US$ Million)

Table 9 Global Neurofibromatosis Type 2 Market Value, By End-User, 2023, 2027 & 2031 (US$ Million)

Table 10 Global Neurofibromatosis Type 2 Market Value, By End-User, 2022-2031 (US$ Million)

Table 11 Global Neurofibromatosis Type 2 Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 12 Global Neurofibromatosis Type 2 Market Value, By Region, 2022-2031 (US$ Million)

Table 13 North America Neurofibromatosis Type 2 Market Value, By Tumor Type, 2022-2031 (US$ Million)

Table 14 North America Neurofibromatosis Type 2 Market Value, By Treatment Type, 2022-2031 (US$ Million)

Table 15 North America Neurofibromatosis Type 2 Market Value, By End-User, 2022-2031 (US$ Million)

Table 16 North America Neurofibromatosis Type 2 Market Value, By Country, 2022-2031 (US$ Million)

Table 17 South America Neurofibromatosis Type 2 Market Value, By Tumor Type, 2022-2031 (US$ Million)

Table 18 South America Neurofibromatosis Type 2 Market Value, By Treatment Type, 2022-2031 (US$ Million)

Table 19 South America Neurofibromatosis Type 2 Market Value, By End-User, 2022-2031 (US$ Million)

Table 20 South America Neurofibromatosis Type 2 Market Value, By Country, 2022-2031 (US$ Million)

Table 21 Europe Neurofibromatosis Type 2 Market Value, By Tumor Type, 2022-2031 (US$ Million)

Table 22 Europe Neurofibromatosis Type 2 Market Value, By Treatment Type, 2022-2031 (US$ Million)

Table 23 Europe Neurofibromatosis Type 2 Market Value, By End-User, 2022-2031 (US$ Million)

Table 24 Europe Neurofibromatosis Type 2 Market Value, By Country, 2022-2031 (US$ Million)

Table 25 Asia-Pacific Neurofibromatosis Type 2 Market Value, By Tumor Type, 2022-2031 (US$ Million)

Table 26 Asia-Pacific Neurofibromatosis Type 2 Market Value, By Treatment Type, 2022-2031 (US$ Million)

Table 27 Asia-Pacific Neurofibromatosis Type 2 Market Value, By End-User, 2022-2031 (US$ Million)

Table 28 Asia-Pacific Neurofibromatosis Type 2 Market Value, By Country, 2022-2031 (US$ Million)

Table 29 Middle East & Africa Neurofibromatosis Type 2 Market Value, By Tumor Type, 2022-2031 (US$ Million)

Table 30 Middle East & Africa Neurofibromatosis Type 2 Market Value, By Treatment Type, 2022-2031 (US$ Million)

Table 31 Middle East & Africa Neurofibromatosis Type 2 Market Value, By End-User, 2022-2031 (US$ Million)

Table 32 Manus Aktteva Biopharma LLP: Overview

Table 33 Manus Aktteva Biopharma LLP: Product Portfolio

Table 34 Manus Aktteva Biopharma LLP: Key Developments

Table 35 AstraZeneca Plc: Overview

Table 36 AstraZeneca Plc: Product Portfolio

Table 37 AstraZeneca Plc: Key Developments

Table 38 OCEAN PHARMACEUTICAL: Overview

Table 39 OCEAN PHARMACEUTICAL: Product Portfolio

Table 40 OCEAN PHARMACEUTICAL: Key Developments

Table 41 Vivace Therapeutics: Overview

Table 42 Vivace Therapeutics: Product Portfolio

Table 43 Vivace Therapeutics: Key Developments

Table 44 Ikena Oncology, Inc.: Overview

Table 45 Ikena Oncology, Inc.: Product Portfolio

Table 46 Ikena Oncology, Inc.: Key Developments

Table 47 Recursion Pharmaceuticals Inc.: Overview

Table 48 Recursion Pharmaceuticals Inc.: Product Portfolio

Table 49 Recursion Pharmaceuticals Inc.: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Neurofibromatosis Type 2 Market Value, 2022-2031 (US$ Million)

Figure 2 Global Neurofibromatosis Type 2 Market Share, By Tumor Type, 2022 & 2031(%)

Figure 3 Global Neurofibromatosis Type 2 Market Share, By Treatment Type, 2022 & 2031(%)

Figure 4 Global Neurofibromatosis Type 2 Market Share, By End-User, 2022 & 2031(%)

Figure 5 Global Neurofibromatosis Type 2 Market Share, By Region, 2022 & 2031(%)

Figure 6 Global Neurofibromatosis Type 2 Market Y-o-Y Growth, By Tumor Type, 2023-2031 (%)

Figure 7 Vestibular Schwannomas Neurofibromatosis Type 2 Market Value, 2022-2031 (US$ Million)

Figure 8 Meningiomas Neurofibromatosis Type 2 Market Value, 2022-2031 (US$ Million)

Figure 9 Other Tumors Neurofibromatosis Type 2 Market Value, 2022-2031 (US$ Million)

Figure 10 Global Neurofibromatosis Type 2 Market Y-o-Y Growth, By Treatment Type, 2023-2031 (%)

Figure 11 Surgery Treatment Type in Global Neurofibromatosis Type 2 Market Value, 2022-2031 (US$ Million)

Figure 12 Radiation Therapy Treatment Type in Global Neurofibromatosis Type 2 Market Value, 2022-2031 (US$ Million)

Figure 13 Drug Therapy Treatment Type in Global Neurofibromatosis Type 2 Market Value, 2022-2031 (US$ Million)

Figure 14 Others Treatment Type in Global Neurofibromatosis Type 2 Market Value, 2022-2031 (US$ Million)

Figure 15 Global Neurofibromatosis Type 2 Market Y-o-Y Growth, By End-User, 2023-2031 (%)

Figure 16 Hospitals End-User in Global Neurofibromatosis Type 2 Market Value, 2022-2031 (US$ Million)

Figure 17 Cancer Centers End-User in Global Neurofibromatosis Type 2 Market Value, 2022-2031 (US$ Million)

Figure 18 Others End-User in Global Neurofibromatosis Type 2 Market Value, 2022-2031 (US$ Million)

Figure 19 Global Neurofibromatosis Type 2 Market Y-o-Y Growth, By Region, 2023-2031 (%)

Figure 20 North America Neurofibromatosis Type 2 Market Value, 2022-2031 (US$ Million)

Figure 21 Asia-Pacific Neurofibromatosis Type 2 Market Value, 2022-2031 (US$ Million)

Figure 22 Europe Neurofibromatosis Type 2 Market Value, 2022-2031 (US$ Million)

Figure 23 South America Neurofibromatosis Type 2 Market Value, 2022-2031 (US$ Million)

Figure 24 Middle East and Africa Neurofibromatosis Type 2 Market Value, 2022-2031 (US$ Million)

Figure 25 North America Neurofibromatosis Type 2 Market Value, 2022-2031 (US$ Million)

Figure 26 North America Neurofibromatosis Type 2 Market Share, By Tumor Type, 2022 & 2031(%)

Figure 27 North America Neurofibromatosis Type 2 Market Share, By Treatment Type, 2022 & 2031(%)

Figure 28 North America Neurofibromatosis Type 2 Market Share, By End-User, 2022 & 2031(%)

Figure 29 North America Neurofibromatosis Type 2 Market Share, By Country, 2022 & 2031(%)

Figure 30 South America Neurofibromatosis Type 2 Market Value, 2022-2031 (US$ Million)

Figure 31 South America Neurofibromatosis Type 2 Market Share, By Tumor Type, 2022 & 2031(%)

Figure 32 South America Neurofibromatosis Type 2 Market Share, By Treatment Type, 2022 & 2031(%)

Figure 33 South America Neurofibromatosis Type 2 Market Share, By End-User, 2022 & 2031(%)

Figure 34 South America Neurofibromatosis Type 2 Market Share, By Country, 2022 & 2031(%)

Figure 35 Europe Neurofibromatosis Type 2 Market Value, 2022-2031 (US$ Million)

Figure 36 Europe Neurofibromatosis Type 2 Market Share, By Tumor Type, 2022 & 2031(%)

Figure 37 Europe Neurofibromatosis Type 2 Market Share, By Treatment Type, 2022 & 2031(%)

Figure 38 Europe Neurofibromatosis Type 2 Market Share, By End-User, 2022 & 2031(%)

Figure 39 Europe Neurofibromatosis Type 2 Market Share, By Country, 2022 & 2031(%)

Figure 40 Asia-Pacific Neurofibromatosis Type 2 Market Value, 2022-2031 (US$ Million)

Figure 41 Asia-Pacific Neurofibromatosis Type 2 Market Share, By Tumor Type, 2022 & 2031(%)

Figure 42 Asia-Pacific Neurofibromatosis Type 2 Market Share, By Treatment Type, 2022 & 2031(%)

Figure 43 Asia-Pacific Neurofibromatosis Type 2 Market Share, By End-User, 2022 & 2031(%)

Figure 44 Asia-Pacific Neurofibromatosis Type 2 Market Share, By Country, 2022 & 2031(%)

Figure 45 Middle East & Africa Neurofibromatosis Type 2 Market Value, 2022-2031 (US$ Million)

Figure 46 Middle East & Africa Neurofibromatosis Type 2 Market Share, By Tumor Type, 2022 & 2031(%)

Figure 47 Middle East & Africa Neurofibromatosis Type 2 Market Share, By Treatment Type, 2022 & 2031(%)

Figure 48 Middle East & Africa Neurofibromatosis Type 2 Market Share, By End-User, 2022 & 2031(%)

Figure 49 Manus Aktteva Biopharma LLP: Financials

Figure 50 AstraZeneca Plc: Financials

Figure 51 OCEAN PHARMACEUTICAL: Financials

Figure 52 Vivace Therapeutics : Financials

Figure 53 Ikena Oncology, Inc.: Financials

Figure 54 Recursion Pharmaceuticals Inc.: Financials

글로벌 신경섬유종증 2형 시장 – 2023-2030

Global Neurofibromatosis Type 2 Market - 2023-2030